R Squared Ltd Sells 360 Shares of argenex SE $ARGX

R Squared Ltd cut its holdings in argenex SE (NASDAQ:ARGX) by 26.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 980 shares of the company’s stock after selling 360 shares during the period. R Squared Ltd’s holdings in argenex were worth $540,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the business. Janney Montgomery Scott LLC boosted its holdings in shares of argenex by 41.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,141 shares of the company’s stock worth $675,000 after buying an additional 335 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of argenex during the 1st quarter valued at $583,000. Oppenheimer & Co. Inc. boosted its stake in argenex by 10.2% during the first quarter. Oppenheimer & Co. Inc. now owns 915 shares of the company’s stock worth $542,000 after acquiring an additional 85 shares in the last quarter. Golden State Wealth Management LLC bought a new position in argenex during the first quarter worth $44,000. Finally, Sequoia Financial Advisors LLC grew its holdings in argenex by 1.3% in the first quarter. Sequoia Financial Advisors LLC now owns 1,829 shares of the company’s stock worth $1,083,000 after purchasing an additional 24 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ARGX. Stifel Nicolaus set a $882.00 price objective on shares of argenex in a report on Thursday, September 18th. Zacks Research downgraded argenex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft downgraded argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. Finally, JPMorgan Chase & Co. increased their target price on argenex from $775.00 to $830.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $817.53.

argenex Stock Performance

argenex stock opened at $812.18 on Friday. The stock has a market cap of $50.01 billion, a PE ratio of 41.65, a price-to-earnings-growth ratio of 0.88 and a beta of 0.46. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $855.46. The firm’s 50-day simple moving average is $749.39 and its 200 day simple moving average is $642.73.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. As a group, analysts predict that argenex SE will post 3.13 EPS for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.